Utah Suspends Doctronic AI Prescription Pilot
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Utah Medical Licensing Board demanded the immediate suspension of Utah’s AI pilot with Doctronic after learning of the program only after it launched.
- Doctronic's pilot lets a chatbot evaluate patients and recommend prescription renewals for nearly 200 chronic‑condition drugs, with the state planning to phase out physician review.
- State-level AI regulation is fragmented, with at least 47 states considering over 250 bills on bias audits, payment policy, and patient consent; California bars insurers from using AI to deny coverage and Colorado mandates bias assessments.
- The FDA's device‑approval framework is built for static products and cannot keep pace with adaptive generative AI systems that receive continual updates.
- A 2025 Kenya study of nearly 40,000 primary‑care visits found AI‑supported clinicians made substantially fewer diagnostic and treatment errors, and the NOHARM trial (published December) showed doctors did not outperform the strongest large language models on routine tasks.
Why it matters: Utah patients risk delayed prescription renewals while insurers confront patchwork state rules, and the lack of a federal AI‑doctor licensing standard hampers scaling of AI that can offset a projected shortage of tens of thousands of physicians.
